CITIGROUP INC - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 146 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.32 and the average weighting 2.3%.

Quarter-by-quarter ownership
CITIGROUP INC ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$3,599,416
+171.7%
470,512
+165.3%
0.00%
+200.0%
Q2 2023$1,324,715
-71.1%
177,338
-74.2%
0.00%
-66.7%
Q1 2023$4,590,461
+155.7%
688,225
+195.6%
0.00%
+200.0%
Q4 2022$1,795,096
+4.4%
232,827
+44.1%
0.00%0.0%
Q3 2022$1,719,000
+1619.0%
161,560
+1213.5%
0.00%
Q2 2022$100,000
-5.7%
12,300
-17.4%
0.00%
Q1 2022$106,000
-97.5%
14,899
-93.9%
0.00%
-100.0%
Q4 2021$4,186,000
+301.7%
244,357
+439.5%
0.00%
+100.0%
Q3 2021$1,042,000
+2716.2%
45,294
+4402.4%
0.00%
Q2 2021$37,0001,0060.00%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q3 2022
NameSharesValueWeighting ↓
Kinnevik AB (publ) 10,405,668$77,730,340100.00%
Data Collective IV GP, LLC 5,941,120$44,380,16632.86%
MV Management XI, L.L.C. 1,971,908$14,730,15325.77%
MIC Capital Management UK LLP 8,451,758$63,134,63512.84%
Yong Rong (HK) Asset Management Ltd 1,174,200$8,7723.85%
ArchPoint Investors 1,114,626$8,326,2563.22%
PLATINUM INVESTMENT MANAGEMENT LTD 2,711,148$20,252,2760.70%
HARVARD MANAGEMENT CO INC 882,129$6,5900.65%
Diametric Capital, LP 119,906$895,6980.40%
Lingotto Investment Management LLP 775,077$5,789,8250.37%
View complete list of RECURSION PHARMACEUTICALS IN shareholders